Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4%
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 290,597 shares, a decrease of 25.4% from the February 12th total of 389,363 shares. Approximately 0.7% of the company's stock are sold short. Based on an
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Volatility and Risk VYNE Therapeutics has a
What Makes Vivani Medical (VANI) a New Buy Stock
Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
On Wednesday, Vivani Medical, Inc. VANI said it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company.
Vivani reports start of first human trial of GLP-1 implant, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating and $4 price target on Vivani Medical shares after the company announced that the first-in-human clinical trial of NPM-115, an exenatide implant based on the company's NanoPortal platform technology, has started patient screening and enrollment at two clinical sites in Australia. The firm believes that NPM-115 has the potential to show comparable efficacy to semaglutide with twice-yearly administration, the analyst tells investors in a research note. In addition, H.C. Wainwright thinks the company could choose to raise additional capital within the next 12 months.
